Unichem Laboratories Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Pabitra Kumar Bhattacharya

İcra Kurulu Başkanı

₹29.2m

Toplam tazminat

CEO maaş yüzdesi	64.3%
CEO görev süresi	1.4yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	12.4yrs
Yönetim Kurulu ortalama görev süresi	1.4yrs

Son yönetim güncellemeleri

Recent updates

Revenues Tell The Story For Unichem Laboratories Limited (NSE:UNICHEMLAB) As Its Stock Soars 26%

Nov 02

It's A Story Of Risk Vs Reward With Unichem Laboratories Limited (NSE:UNICHEMLAB)

Sep 13

Optimistic Investors Push Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares Up 26% But Growth Is Lacking

Feb 06

There's Reason For Concern Over Unichem Laboratories Limited's (NSE:UNICHEMLAB) Massive 28% Price Jump

Jul 23

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Jul 15

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Jul 01

Unichem Laboratories (NSE:UNICHEMLAB) Is Making Moderate Use Of Debt

Nov 27

Investors Shouldn't Be Too Comfortable With Unichem Laboratories' (NSE:UNICHEMLAB) Robust Earnings

Jun 05

Should Unichem Laboratories Limited (NSE:UNICHEMLAB) Be Part Of Your Income Portfolio?

Mar 02

Unichem Laboratories Limited's (NSE:UNICHEMLAB) Stock's Been Going Strong: Could Weak Financials Mean The Market Will Correct Its Share Price?

Feb 09

Should You Take Comfort From Insider Transactions At Unichem Laboratories Limited (NSE:UNICHEMLAB)?

Jan 19

Do Institutions Own Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares?

Dec 29

Is Unichem Laboratories (NSE:UNICHEMLAB) Weighed On By Its Debt Load?

Dec 10

Key Things To Understand About Unichem Laboratories' (NSE:UNICHEMLAB) CEO Pay Cheque

Nov 23

Did Unichem Laboratories' (NSE:UNICHEMLAB) Share Price Deserve to Gain 41%?

Nov 02

Should You Buy Unichem Laboratories Limited (NSE:UNICHEMLAB) For Its 1.5% Dividend?

Oct 13

How Much Are Unichem Laboratories Limited (NSE:UNICHEMLAB) Insiders Spending On Buying Shares?

Sep 16

Is Unichem Laboratories (NSE:UNICHEMLAB) Using Too Much Debt?

Aug 26

Is Unichem Laboratories Limited's (NSE:UNICHEMLAB) Shareholder Ownership Skewed Towards Insiders?

Aug 05

Would Shareholders Who Purchased Unichem Laboratories'(NSE:UNICHEMLAB) Stock Three Years Be Happy With The Share price Today?

Jul 14

CEO Tazminat Analizi

Pabitra Kumar Bhattacharya'un ücretlendirmesi Unichem Laboratories'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-₹56m
Jun 30 2024	n/a	n/a	-₹606m
Mar 31 2024	₹29m	₹19m	-₹705m

Tazminat ve Piyasa: Pabitra Kumar 'nin toplam tazminatı ($USD 340.53K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 256.47K ).

Tazminat ve Kazançlar: Pabitra Kumar şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Pabitra Kumar Bhattacharya (55 yo)

1.4yrs

Görev süresi

₹29,175,000

Tazminat

Mr. Pabitra Kumar Kalipada Bhattacharya had been Managing Director of Krebs Biochemicals & Industries Limited since August 1, 2021 until August 9, 2023 and had been its Additional Director since July 30, 2...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pabitra Kumar Bhattacharya	MD & Director	1.4yrs	₹29.18m	Veri yok
Pradeep Bhandari	Head of Legal	5.4yrs	₹9.84m	Veri yok
Dhananjay Sathe	Chief Scientific & Compliance Officer	no data	Veri yok	Veri yok
Prasad Joshi	Vice President of Human Resources & ER	16.6yrs	₹7.48m	Veri yok
Vinod Behl	Head of Projects & Investments	no data	₹2.10m	Veri yok
Jalesh Burye	Chief Quality & Compliance Officer	no data	Veri yok	Veri yok
Ashwani Kumar	Chief Manufacturing & Compliance Officer	no data	Veri yok	Veri yok
Bhagwat Dhingra	Chief Executive of Domestic Pharma	12.4yrs	₹13.62m	Veri yok
Scott Delaney	President of North America & CEO of North America	6.6yrs	Veri yok	Veri yok
P. Deshpande	Vice President of Chemical of Research and Development	no data	₹593.35k	Veri yok
Gajendra Ghanekar	Vice President of Commercial	24.2yrs	₹6.14m	Veri yok
R. Shapeti	Advisor of Active Pharmaceutical Ingredients (API)	no data	₹5.24m	Veri yok

12.4yrs

Ortalama Görev Süresi

65.5yo

Ortalama Yaş

Deneyimli Yönetim: UNICHEMLAB 'un yönetim ekibi deneyimli ve deneyimlidir ( 12.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pabitra Kumar Bhattacharya	MD & Director	1.4yrs	₹29.18m	Veri yok
Prakash Mody	Chairman	50.6yrs	₹328.40m	16.21% ₹ 8.1b
Arun Todarwal	Independent Director	less than a year	₹100.00k	Veri yok
Pranay Godha	Non-Executive Non-Independent Director	1.4yrs	₹300.00k	Veri yok
Priti Puri	Additional Independent Non-Executive Director	1.8yrs	₹850.00k	Veri yok
Anand Kusre	Independent Director	less than a year	₹100.00k	Veri yok

1.4yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: UNICHEMLAB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/06 18:14
Gün Sonu Hisse Fiyatı	2025/01/06 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Unichem Laboratories Limited 13 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Rakesh Nayudu	Almondz Global Securities Ltd
Sriraam Rathi	Anand Rathi Shares and Stock Brokers Limited
null null	Anand Rathi Shares and Stock Brokers Limited

Unichem Laboratories Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Recent updates

Second quarter 2025 earnings released: EPS: ₹4.34 (vs ₹3.48 loss in 2Q 2024)

Revenues Tell The Story For Unichem Laboratories Limited (NSE:UNICHEMLAB) As Its Stock Soars 26%

Unichem Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024

It's A Story Of Risk Vs Reward With Unichem Laboratories Limited (NSE:UNICHEMLAB)

Unichem Laboratories Limited to Report Q1, 2025 Results on Aug 08, 2024

High number of new directors

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

New major risk - Revenue and earnings growth

Unichem Laboratories Limited to Report Q4, 2024 Results on May 22, 2024

Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023)

Optimistic Investors Push Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares Up 26% But Growth Is Lacking

Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024

Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg

Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023)

Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹3.32 loss in 1Q 2023)

Non-Executive Independent Director recently sold ₹10m worth of stock

Full year 2023 earnings released: ₹28.72 loss per share (vs ₹4.70 profit in FY 2022)

Third quarter 2023 earnings released: ₹9.08 loss per share (vs ₹2.01 loss in 3Q 2022)

Is Unichem Laboratories (NSE:UNICHEMLAB) Using Debt Sensibly?

Krka Reportedly Eyes Promoter Stake in Unichem Laboratories

Insufficient new directors

Second quarter 2023 earnings released: ₹10.04 loss per share (vs ₹1.82 loss in 2Q 2022)

Unichem Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Unichem Laboratories Limited Receives ANDA Approval for Extended Phenytoin Sodium Capsules USP, 100 Mg from United States Food and Drug Administration

Does Unichem Laboratories (NSE:UNICHEMLAB) Have A Healthy Balance Sheet?

Unichem Laboratories Limited Receives ANDA Approval for Carbamazepine Tablets USP

Unichem Laboratories Limited Receives ANDA Approval for Its Quetiapine Extended-Release Tablets

Unichem Laboratories Limited Receives ANDA Approval for its Labetalol Hydrochloride Tablets, USP 100 Mg, 200 Mg, and 300 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022

Unichem Laboratories (NSE:UNICHEMLAB) Is Due To Pay A Dividend Of ₹4.00

Upcoming dividend of ₹4.00 per share

There's Reason For Concern Over Unichem Laboratories Limited's (NSE:UNICHEMLAB) Massive 28% Price Jump

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Full year 2022 earnings released: EPS: ₹4.70 (vs ₹4.88 in FY 2021)

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Unichem Laboratories Limited, Annual General Meeting, Aug 09, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories Limited Recommends Final Dividend for the Year Ended March 31, 2022

Unichem Laboratories Limited to Report Q4, 2022 Results on May 27, 2022

Insufficient new directors

Unichem Laboratories Limited Receives ANDA Approval for Its Divalproex Sodium Extended-Release Tablet

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories (NSE:UNICHEMLAB) Is Making Moderate Use Of Debt

Second quarter 2022 earnings released: ₹1.82 loss per share (vs ₹1.24 profit in 2Q 2021)

Upcoming dividend of ₹4.00 per share

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Receives Tentative USFDA Approval for ANDA of Aripiprazole Tablets

Investors Shouldn't Be Too Comfortable With Unichem Laboratories' (NSE:UNICHEMLAB) Robust Earnings

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Recommends Dividend for the Year Ended March 31, 2021

Unichem Laboratories Limited Announces That It Has Received ANDA Approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg

Insider recently bought ₹2.3m worth of stock

Unichem Laboratories Limited Receives ANDA Approval for Its Guanfacine Tablets, USP 1 Mg and 2 Mg from the United States Food and Drug Administration

Should Unichem Laboratories Limited (NSE:UNICHEMLAB) Be Part Of Your Income Portfolio?

New 90-day high: ₹332

Unichem Laboratories Limited Receives Anda Approval for Its Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited's (NSE:UNICHEMLAB) Stock's Been Going Strong: Could Weak Financials Mean The Market Will Correct Its Share Price?

New 90-day high: ₹295

Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.07 loss in 3Q 2020)

Unichem Laboratories Limited Receives ANDA Approval for its Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg from USFDA